问题 › 对单一客户的过度依赖 › 医疗服务提供商
集中度是否成问题，取决于支付方退出基于价值合同的容易程度，这涉及管理下行风险所需的每期成本数据，而非归属人次的百分比。 对医疗服务提供商而言，问题出现在特定位置。承载答案的数字是每期成本和支付方组合，行业特有的复杂之处在于，已在38,000人次上接受下行风险，却缺乏定价所需的每期成本数据。通用版本的问题与你实际面临的问题，第一步行动不同。
集中度是否成问题，取决于支付方退出基于价值合同的容易程度，这涉及管理下行风险所需的每期成本数据，而非归属人次的百分比。 对医疗服务提供商而言，问题出现在特定位置。承载答案的数字是每期成本和支付方组合，行业特有的复杂之处在于，已在38,000人次上接受下行风险，却缺乏定价所需的每期成本数据。通用版本的问题与你实际面临的问题，第一步行动不同。
绑定38,000归属人次的支付方，危险与否完全取决于底层结构。如果支付方能在一个季度内将这些人次转向其他提供商，那就是生存级暴露。如果转向需要改变网络充足性和护理协议，那就是看似集中却稳固的位置。
陷阱在于，集中通常伴随更差的经济条件——大支付方在共享节约条款上更强硬，要求更多每期成本报告，并在绩效证明前扣款，因此风险和利润损失同时到来。通过增加其他归属人次来稀释集中度很慢，更快的杠杆通常是重新定价基于价值合同，以反映在缺乏每期成本数据情况下承担的下行风险。
还值得区分收入集中和贡献集中。两者可能指向相反方向，而当用每提供商贡献和面板规模衡量时，第二个才是真正会造成伤害的。
这三者同时出现才是标志。单独一个通常指向其他问题。
✓ 单一支付方占据基于价值合同下大部分归属人次
✓ 该支付方在共享节约或报告条款上与其他支付方组合存在实质差异
✓ 失去合同将要求立即调整面板规模或提供商成本，而非按计划进行
通常会让情况更糟的做法。 在其他地方追逐更多归属人次来稀释百分比，这会增加每期成本，却让依赖保持不变。
It is for you if you run or finance a healthcare provider and one customer exceeds a quarter of revenue. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on 一家医疗服务提供商. It is a sample profile rather than a customer, and it is engine output translated from English — this is the format you get, on your own numbers.
The subject is Cedar Ridge Health Partners, a sample company profile used for testing rather than a customer — 38,000 attributed lives under value-based contracts.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Turn 38,000 downside-risk lives into a self-funding 36-month analytics platform via payer co-development.
The leak it closes. Settlement lag (6–9 months) and payer audit adjustments reduced via internal attribution engine
The assumption it rests on. Payer agrees to 5-year exclusivity and 15–25% platform margin split — the engine put the probability at 0.75.
| Investment required | $2.5–3.0M over 18 months |
| Expected return | 7.6–9.1× over three years on $2.5–3.0M investment |
| Revenue, year 1 | $0 (platform build phase) |
| Revenue, year 2 | $6.9–11.4M (first shared-savings settlement) |
| Revenue, year 3 | $13.7–22.8M (full run-rate) |
| Exit criteria | Terminate if payer refuses exclusivity by Month 6 OR if attribution accuracy <80% by Month 18 OR if shared-savings pool < $60M by end of contract year 2 |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to 专有EFF方法论, one of 29 engagements the platform runs. For 医疗服务提供商 it works through cost per episode, payer mix, panel size and contribution per provider, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. 在此阅读完整报告 if you would rather see the depth first.
没有单独的阈值有实质意义。重要的是他们能多快取代你，以及如果他们这么做，你的固定成本会发生什么。两者都能回答。
很少仅因集中度原因拒绝，更多是因利润原因。如果最大账户也是定价最差的，集中度问题和利润问题有相同的解决办法。
提高他们离开的成本，并重新定价风险敞口。发展第二个细分市场是正确的长期答案，但无法在你实际拥有的通知期内提供帮助。
Materially, yes. Downside risk has been accepted on 38,000 lives without the cost-per-episode data needed to price it — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are cost per episode, payer mix, panel size, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on cost per episode and payer mix. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.
English · Español · Deutsch · Português · Français · Italiano · Nederlands · 日本語 · 한국어 · 中文 · Polski · Türkçe · العربية · Tiếng Việt · ไทย · हिन्दी · עברית